Smith & Nephew
Corporate

Select your country

Smith & Nephew

Advanced Search
  • Home
  • About Us
  • Innovation & Products
  • Sustainability
  • Investor Centre
  • News & Media
  • Careers
  • Home
  • Sustainability
  • Policies and Principles
  • Economic Contribution Principles
  • Healthcare Economics
  • Biologics and Clinical Therapies
  • Home >
  • Sustainability >
  • Policies and Principles >
  • Economic Contribution Principles >
  • Healthcare Economics >
  • Biologics and Clinical Therapies
  • Orthopaedics
  • Endoscopy
  • Advanced Wound Management
  • Biologics and Clinical Therapies
    • EXOGEN
    • DUROLANE
    • Biomaterials
    • Cell based therapies
  • Contact
  • Print
  • Forward

Email this page

close
  1. Mandatory fields are marked with an asterisk [*].

    Tell us who you want to send your mail to Fill in your email details

    Note: Smith & Nephew does not collect or make use of the email addresses or names provided here. They are only used to show the recipient who has sent the message.

    Change your message if you want Change the message if you want to

    1. <recipient name> <address>
    2. <sender name> <address>
    3. <sender name> is sending you a link

    4. <sender name>

    Visitor verfication

Email sent successfully
Error: Check all fields are valid. Exclude special characters from Comments field
Smith
Nephew

Biologics and Clinical Therapies


Our Biologics business, together with its Clinical Therapies commercial arm aims to develope and commercialise advanced, locally delivered biological therapies to promote healing and pain relief.

It focuses on three key areas : osteoarthritis and cartilage, bone healing, and soft tissue and infection.

Biologics products already on the market or being developed include :

  • EXOGEN
  • DUROLANE
  • Biomaterials
  • Cell based therapies

 

  • ◊ Trademark of Smith & Nephew
  • Accessibility
  • Terms of Use
  • Copyright & Disclaimer